PMID: 18195670Jan 16, 2008Paper

Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices

Reviews in Neurological Diseases
Gavin GiovannoniTimoth Vartanian

Abstract

Multiple sclerosis (MS) is the most common cause of nontraumatic severe neurological disability in young adults. If left untreated, most individuals with MS will accumulate significant physical and/or cognitive disability as the consequence of demyelination and axonal injury. Treatment has focused on disease-modifying therapies (DMTs) and questions remain about timing and indications for their use. Natalizumab is a humanized monoclonal antibody directed against alpha4-integrin that prevents migration of leukocytes into the brain parenchyma. The clinical and radiological efficacy of natalizumab has been shown in several randomized trials; however, adverse events associated with natalizumab have limited its use as a first-line agent. In this review we compare current recommendations for the use of first-line DMTs, adverse events associated with MS therapies, and differences between the practices in North American and the European Union.

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Related Papers

Expert Opinion on Pharmacotherapy
Alex TselisRobert P Lisak
Archives of Neurology
E Ann YehNational Network of Pediatric MS Centers of Excellence
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
S BelachewM Vokaer
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
Carmen Arnal-GarciaCelia Oreja-Guevara
© 2021 Meta ULC. All rights reserved